

# High Affinity Molecules Disrupting GRB2 Protein Comp Chronic Myelogenous Leukaemia

Leukemia and Lymphoma

44, 411-427

DOI: 10.1080/1042819021000037930

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current Awareness in Hematological Oncology. Hematological Oncology, 2003, 21, 91-98.	1.7	0
2	A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity. Biochemical and Biophysical Research Communications, 2003, 310, 378-383.	2.1	35
3	Development of l-3-aminotyrosine suitably protected for the synthesis of a novel nonphosphorylated hexapeptide with low-nanomolar Grb2-SH2 domain-binding affinity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 3205-3208.	2.2	13
4	Animal models of chronic myelogenous leukemia. Hematology/Oncology Clinics of North America, 2004, 18, 525-543.	2.2	12
5	Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity. Bioorganic and Medicinal Chemistry, 2005, 13, 4200-4208.	3.0	13
6	Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1385-1388.	2.2	13
7	Examination of Phosphoryl-Mimicking Functionalities within a Macrocyclic Grb2 SH2 Domain-Binding Platform. Journal of Medicinal Chemistry, 2005, 48, 3945-3948.	6.4	24
8	Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies. Gene, 2006, 374, 26-38.	2.2	19
9	Facile synthesis and application of uniformly <sup>13</sup> C, <sup>15</sup> N-labeled phosphotyrosine for ligand binding studies. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3806-3808.	2.2	2
10	Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors. Current Pharmaceutical Design, 2006, 12, 529-548.	1.9	44
11	The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells. Biochemical Pharmacology, 2008, 75, 2080-2091.	4.4	17
12	Grb2 signaling in cell motility and cancer. Expert Opinion on Therapeutic Targets, 2008, 12, 1021-1033.	3.4	162
13	Tnk1/Kos1 Knockout Mice Develop Spontaneous Tumors. Cancer Research, 2008, 68, 8723-8732.	0.9	33
14	Distinct Binding Modes of Two Epitopes in Gab2 that Interact with the SH3C Domain of Grb2. Structure, 2009, 17, 809-822.	3.3	69
15	Grb2 and Other Adaptor Proteins in Tumor Metastasis. Cancer Metastasis - Biology and Treatment, 2010, , 77-102.	0.1	1
16	Inhibition of Grb2 expression demonstrates an important role in BCR/ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia, 2011, 25, 305-312.	7.2	43
17	Induction of the Ras activator Son of Sevenless 1 by environmental pollutants mediates their effects on cellular proliferation. Biochemical Pharmacology, 2011, 81, 304-313.	4.4	30
18	Unusual binding of Grb2 protein to a bivalent polyproline-ligand immobilized on a SPR sensor: Intermolecular bivalent binding. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 524-535.	2.3	1

#	ARTICLE	IF	CITATIONS
20	Insights into the Shc Family of Adaptor Proteins. Journal of Molecular Signaling, 2017, 12, 2.	0.5	34
22	GRB2 Signaling as a Molecular Target for Cancer. , 2012, , 1-22.		1
23	Potential pharmacological mechanisms of tanshinone IIA in the treatment of human neuroblastoma based on network pharmacological and molecular docking Technology. Frontiers in Pharmacology, 0, 15, .	3.5	0